Screener
Travere Therapeutics, Inc. TVTX Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Travere Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
FAQ
- What is Travere Therapeutics, Inc.'s gross margin?
- Travere Therapeutics, Inc. (TVTX) reported gross margin of 98.6% in Q1 2026.
- How has Travere Therapeutics, Inc.'s gross margin changed year-over-year?
- Travere Therapeutics, Inc.'s gross margin increased by 2.7% year-over-year, from 96% to 98.6%.
- What is the long-term trend for Travere Therapeutics, Inc.'s gross margin?
- Over 4 years (2020 to 2025), Travere Therapeutics, Inc.'s gross margin has grown at a 0.3% compound annual growth rate (CAGR), from 96.9% to 97.9%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.
Ask your AI about Travere Therapeutics, Inc.'s gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude